نتایج جستجو برای: atomoxetine

تعداد نتایج: 721  

2017
Sally Shaywitz Bennett Shaywitz Linda Wietecha Sharon Wigal Keith McBurnett David Williams William G. Kronenberger Stephen R. Hooper

OBJECTIVES Evaluated the effects of atomoxetine on the reading abilities of children with dyslexia only or attention-deficit/hyperactivity disorder (ADHD) and comorbid dyslexia. METHODS Children aged 10-16 years (N = 209) met Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria for dyslexia only (n = 58), ADHD and comorbid dyslexia (n = 124), ...

2011
Tracey W Tsang Michael R Kohn Daniel F Hermens Simon D Clarke C Richard Clark Daryl Efron Noel Cranswick Chris Lamb Leanne M Williams

BACKGROUND The ACTION study (Attention deficit hyperactivity disorder Controlled Trial Investigation Of a Non-stimulant) is a multi-center, double-blind, randomized cross-over trial of the non-stimulant medication, Atomoxetine, in children and adolescents with attention deficit hyperactivity disorder (ADHD). The primary aims are to examine the efficacy of atomoxetine for improving cognition and...

Journal: :Journal of psychopharmacology 2016
Hsing-Chang Ni Shoou-Lian Hwang Gu Hsiang-Yuan Lin Yu-Ju Lin Li-Kuang Yang Hui-Chun Huang Susan Shur-Fen Gau

OBJECTIVE Intra-individual variability in reaction time (IIV-RT) is common in individuals with attention-deficit/hyperactivity disorder (ADHD). It can be improved by stimulants. However, the effects of atomoxetine on IIV-RT are inconclusive. We aimed to investigate the effects of atomoxetine on IIV-RT, and directly compared its efficacy with methylphenidate in adults with ADHD. METHODS An 8-1...

Journal: :Journal of pharmacological sciences 2009
Rie Tsuchida Masahiro Kubo Mariko Kuroda Yasuhiro Shibasaki Norihito Shintani Michikazu Abe Katalin Köves Hitoshi Hashimoto Akemichi Baba

It has been demonstrated that treatment of hyperactive mice with psychostimulants produced a calming effect depending on serotonergic neurotransmission. Our previous study also showed that hyperactivity in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP) was ameliorated by amphetamine in a serotonin (5-HT)(1A)-dependent manner and that amphetamine calmed wild-type mice gi...

Journal: :Journal of child and adolescent psychopharmacology 2006
Pieter W Troost Mark-Peter Steenhuis Hanneke G Tuynman-Qua Luuk J Kalverdijk Jan K Buitelaar Ruud B Minderaa Pieter J Hoekstra

OBJECTIVE This pilot study examined the effects of atomoxetine on attention-deficit/hyperactivity disorder (ADHD) symptoms and autistic features in children with pervasive developmental disorders (PDD). METHOD Twelve children (aged 6-14 years) with PDD accompanied by ADHD symptoms entered a 10-week open-label study with atomoxetine (1.19 +/- 0.41 mg/kg/day). Response was assessed by using par...

2017
Elise E. DeVito Aryeh I. Herman Noah S. Konkus Huiping Zhang Mehmet Sofuoglu

Data presented are from a sex-differences secondary analysis of a human laboratory investigation of single doses of atomoxetine (40 mg and 80 mg) versus placebo in abstinent individuals with cocaine use disorders (CUD). Subjective drug effects, cognitive performance and cardiovascular measures were assessed. The primary atomoxetine dose analyses (which do not consider sex as a factor) are repor...

2009
A. Marquand S. De Simoni O. O'Daly F. Zelaya M. Mehta

Introduction Methylphenidate and atomoxetine are two psychoactive drugs routinely used for treatment of attention deficit/hyperactivity disorder (AD/HD), but little is known about their differential brain physiology in humans. We sought to directly discriminate between the cerebral effects of methylphenidate and atomoxetine in healthy volunteers at rest by applying exploratory pattern recogniti...

2011
Pashtoon Murtaza Kasi Rawad Mounzer George H. Gleeson

Attention deficit hyperactivity disorder (ADHD) is one of the most common neurobehavioral disorders of childhood and adolescence. Classically, stimulants have been used in the treatment of this condition. Atomoxetine (Strattera; Eli Lilly and Company) is a selective norepinephrine reuptake inhibitor (SNRI), one of the first medications in the nonstimulant class of medications that has been appr...

Journal: :The Journal of pharmacology and experimental therapeutics 2014
Sean R Jesinkey Midhun C Korrapati Kyle A Rasbach Craig C Beeson Rick G Schnellmann

Skeletal muscle atrophy remains a clinical problem in numerous pathologic conditions. β2-Adrenergic receptor agonists, such as formoterol, can induce mitochondrial biogenesis (MB) to prevent such atrophy. Additionally, atomoxetine, an FDA-approved norepinephrine reuptake inhibitor, was positive in a cellular assay for MB. We used a mouse model of dexamethasone-induced skeletal muscle atrophy to...

2015
Hsiang-Yuan Lin Susan Shur-Fen Gau

BACKGROUND Although atomoxetine demonstrates efficacy in individuals with attention-deficit hyperactivity disorder, its treatment effects on brain resting-state functional connectivity remain unknown. Therefore, we aimed to investigate major brain functional networks in medication-naïve adults with attention-deficit hyperactivity disorder and the efficacy of atomoxetine treatment on resting-sta...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید